TSPYL2 and diabetic kidney disease: Based on these results, tamoxifen administration at 1.5 mg per day for 3 consecutive days was used to delete CDA1 in the diabetic kidney disease model in CDA1Flox/ERCre mice in order to examine the effect of targeted deletion of CDA1 on the progression of renal injury after establishment of diabetic kidney disease.